@article{ref1,
title="Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study",
journal="Journal of Alzheimer's disease",
year="2016",
author="Shelef, Assaf and Barak, Yoram and Berger, Uri and Paleacu, Diana and Tadger, Shelly and Plopsky, Igor and Baruch, Yehuda",
volume="51",
number="1",
pages="15-19",
abstract="BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). <br><br>OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). <br><br>METHODS: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. <br><br>RESULTS: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p <  0.01) and NPI score were recorded (44.4 to 12.8; p <  0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, and sleep and caregiver distress. <br><br>CONCLUSION: Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.<p /> <p>Language: en</p>",
language="en",
issn="1387-2877",
doi="10.3233/JAD-150915",
url="http://dx.doi.org/10.3233/JAD-150915"
}